Although the company refused to comment, then AstraZeneca to 12 per cent to ￡ 30,28.
Analysts suggest that a sale of Astra Tech release cash that can be used to increase the share buyback or finance bolted acquisitions.
Brian White, capital of the coast, analyst says that speculation is surprising since the unit seems to non-essential considering undertaking its focus on its pharmaceutical activities.
"If confirmed, AstraZeneca seems follow the footsteps of other major pharma companies seeking to benefit from transfers of assets to boost their income generation and cash operating", he added.
But AstraZeneca increases failed wake the marchés.Parmi concerns that China will intensify measures to curb inflation mounting, minor shed blood of most with Antofagasta sliding 79 p to ￡ 13.59, Kazakhmys down 93% to ￡ 14.21 and Fresnillo, losing 92 percent ￡ 13.61.
Chinese concerns pressed already nervous market, with some uncertain if Ireland investors accept a European bailout.Ireland, as well as other countries in the euro area, situation have on financial stocks.Lloyd's Banking Group throw 3.27 to 66.6%, while the Royal Bank of Scotland lost 1.46 percent geared.
British Airways has also under buildup.the airline fell 10.9 259?p Union representing staff cabin opted not to recommend an agreement proposed to put an end to a year with management conflict.
With financial and mining exploitation heavy on the slide, the FTSE 100 tumbling in the territory of Tin hat, dive points 5681.9, 138.51. 9bn ￡ 35 off the coast of the index wiping.The last large capitalization fell by such a large margin was 11 August of this year, when concerns about the American and Chinese economy sent merchants running for the couverture.Le FTSE 250 was 10717.73 205.47 points.
Riding high, however, was Rexam .the manufacturer of Carlsberg beverage cans and Red Bull p 318.2 pink 7.2 after what he said wait for results of the second half to conform to expectations with strong growth in South America was offset lower sales in Europe and North America
Investors seek advice when Rexam will sign new contracts in the Nord.Même America if Graham Chipchase Rexam Chief Executive says no contracts had yet been signed, he said the next step was "largely on crossing them the t's and dotting the East". ""
The Soujeole, Seymour Pierce analyst Caroline said: "" concerns about the outcome of these contractual negotiations were held actions on these last months; comment this morning should go some way to allay the fears of investors. ""
Join Rexam was living, which, according to the effects of an outbreak of Numis analysts.as an update of outsourcing group, said Thursday, should reassure investors that capita model provides always two chiffres.Numis revenue growth increased its rating on back-office "buy" specialist "add", pushing living 3.5 to 735 p.
Among the second liners, Sportingbet conducted a u-turn, shift from 3.6 to 59.7%, after online games said Swedish rival, Unibet, undertaking had left merger talks.
Hostels in company was among latecomers too, 10.3 99,3%.Pubs said Britain group it does not pay a dividend in the year and has warned that the economic environment remains difficult.
But analysts have been remains positive, with BarCap say that after eliminations of bottom-end pubs, it believes that the Group was well positioned to withstand additional pressure increases in VAT and austerity measures which is kick in 2011.
In emerge was better Homeserve, thanks to positive UBS which has increased the "buy" to "neutral".the broker house insurance group advised in weak recent and raised its price target to 510 p 450 p, pushing 15.8 Homeserve 429,6 p.
Far from the main market, AIM listed ReNeuron surged 2.95 to 7.85% after an innovative trial to test the safety of persons stem cell therapy disabled by strokes the beginning of the company.
Doctors in Scotland, in collaboration with ReNeuron, injected in their first patient, who was released safely to the hospital two days later brain stem cells.
It is hoped that neural stem cells can repair the areas damaged by a stroke, improve mental function and physique.Cependant, the first trial is designed primarily to test whether the experimental treatment is safe for patients.
Analysts matrix described the event as a "critical stage", that "significantly deviate company."
Elsewhere on AIM, Vectura, also on the rise, earned 4 68.25 p.Vectura specializes in inhaled medicines, has posted an increase in first-half 15pc recipes.
Also stimulate a sense was news that Sandoz - a division of Novartis - ordered its first batch of inhalers Vectura.SANDOZ devices is the European partner V315 de Vectura, which is regarded as a potential generic Advair version, drug lung GlaxoSmithKline closed .Glaxo 8? to ￡ 12.13? .Analystes KBC Peel hunt preserved their "buy" rating on Vectura say the pipeline grew well.
View the original article here
07:23
zhbjzhql
, Posted in
